Novel effector monocytes against human RBC antigens invading rejected renal allografts.
A novel effector SPFC-MO may be involved in human renal allograft rejection, and the involvement of SPFC in rejected grafts may be reflected by the preoperative antidonor SPFC reactivity detected by the MLC-SPFC assay.